ArticleCirculation reports2019
Long-Term Tolvaptan Treatment in Refractory Heart Failure.
Article in Circulation reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Tolvaptan in heart failure: Contemporary evidence and a framework for precision decongestion.Heart failure reviews · 2026Review
- Mid-Term Impact of Kampo Goreisan in Patients with Congestive Heart Failure Receiving Tolvaptan-Incorporated Medical Therapy.Journal of clinical medicine · 2026Article
- Severe tolvaptan-associated hyperglycemia: a case report.Journal of medical case reports · 2025Article
- Uncovering the molecular mechanisms of tonifying kidney and activating blood Decoction against myocardial fibrosis using network Pharmacology and experimental validation.Scientific reports · 2025Article
- Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age.BMC cardiovascular disorders · 2022Article
- Temporal Change in Renoprotective Effect of Tolvaptan on Patients with Heart Failure: AURORA Study.Journal of clinical medicine · 2022Article
- Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure.Heart and vessels · 2021Observational
- Temporal trends of a vasopressin VESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.